Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
Healthy Volunteers
NCT07430007

Exercise and Dietary Lifestyle Intervention on Reducing Atrial Fibrillation Burden, Cardiac and Body Fat Mass.

Led by University of Eastern Finland · Updated on 2026-02-24

158

Participants Needed

4

Research Sites

165 weeks

Total Duration

On this page

Sponsors

U

University of Eastern Finland

Lead Sponsor

K

Kuopio University Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is strongly associated with obesity and excess body fat. Lifestyle interventions, including exercise and dietary modification, may reduce AF burden, but long-term randomized controlled trial evidence with objective AF burden assessment and advanced cardiac imaging is limited. The MOVE-AF trial is a randomized controlled trial designed to evaluate whether a 12-month tailored exercise and dietary lifestyle intervention, compared with usual care, reduces atrial fibrillation burden and symptom severity and decreases cardiac and total body fat mass in overweight and obese adults with paroxysmal or persistent AF.

CONDITIONS

Official Title

Exercise and Dietary Lifestyle Intervention on Reducing Atrial Fibrillation Burden, Cardiac and Body Fat Mass.

Who Can Participate

Age: 18Years - 75Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18-75 years
  • Body mass index (BMI) ≥27 kg/m²
  • Documented paroxysmal or persistent atrial fibrillation
  • Ability to participate in exercise training and follow study procedures
  • Access to a smartphone or device for rhythm monitoring
  • Provides written informed consent
Not Eligible

You will not qualify if you...

  • Permanent atrial fibrillation
  • Unstable angina or acute coronary syndrome within the past 3 months
  • Participation in other lifestyle or drug weight reduction trials
  • Left ventricular ejection fraction below 30%
  • Severe valvular heart disease or planned cardiac surgery
  • Severe heart failure (NYHA class IV) or severe angina (CCS class IV)
  • Unstable coronary artery disease or recent heart attack
  • Severe lung disease limiting exercise
  • Active cancer
  • Autoimmune or systemic inflammatory diseases
  • Severe kidney or liver failure
  • Memory disease or significant cognitive impairment
  • Unstable psychiatric condition
  • Recent joint or back surgery within 6 months
  • Ongoing back or joint pain preventing exercise
  • Contraindications to exercise testing or training
  • Pregnancy or breastfeeding
  • Participation in another interventional study
  • Any condition making participation unsafe or not possible

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Hospital Nova of Central Finland

Jyväskylä, Central Finland, Finland

Actively Recruiting

2

University of Eastern Finland

Kuopio, Eastern Finland, Finland

Not Yet Recruiting

3

Kuopio University Hospital

Kuopio, Northern Savonia, Finland

Not Yet Recruiting

4

Tampere University Hospital

Tampere, Finland

Not Yet Recruiting

Loading map...

Research Team

J

Jari Laukkanen, MD, PhD

CONTACT

M

Merja Perhonen, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here